Edition:
United Kingdom

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

69.48EUR
2:25pm BST
Change (% chg)

€-2.10 (-2.93%)
Prev Close
€71.58
Open
€71.08
Day's High
€71.44
Day's Low
€68.10
Volume
1,399,511
Avg. Vol
662,658
52-wk High
€93.82
52-wk Low
€68.10

Select another date:

Wed, Oct 17 2018

UPDATE 1-Fresenius Medical cuts 2018 targets, sending shares tumbling

* FMC shares slump 13.7 pct, Fresenius down 8.9 pct (Recasts, adds outlook, analyst, trader comment, changes dateline)

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT, June 11 Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

BRIEF-Fresenius Medical Care CEO: Looking To Pick-Up M&A Pace

* CEO TELLS Q1 ANALYST CALL WE ARE LOOKING TO BE MORE ACTIVE IN THE ACQUISITION ARENA; IT'S SMALL THINGS Further company coverage: (Reporting By Berlin Newsroom)

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

Fresenius Medical cuts 2018 sales target after drug dosage shift

BERLIN German dialysis specialist Fresenius Medical Care cut its 2018 sales target due to lower than expected doses of calcimimetic drugs at its dialysis service business in the United States.

Fresenius Medical cuts 2018 sales target after drug dosage shift

BERLIN German dialysis specialist Fresenius Medical Care cut its 2018 sales target due to lower than expected doses of calcimimetic drugs at its dialysis service business in the United States.

UPDATE 1-Fresenius Medical cuts 2018 sales target after drug dosage shift

* Now sees 2018 revenue growth of 5-7 pct at constant currency

Fresenius Medical sells U.S. Sound Inpatient for $2.15 billion

BERLIN German dialysis specialist Fresenius Medical Care is selling its majority shareholding in Sound Inpatient Physicians Holdings for $2.15 billion, it said on Saturday.

Select another date: